Juliane Winkler

Juliane Winkler

Auto-generated profile, based on publicly available information

Juliane Winkler

Center for Cancer Research, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJuliane Winkler
Juliane Winkler
AAAbisola Abisoye-Ogunniyan
Abisola Abisoye-Ogunniyan
KMKevin J. Metcalf
Kevin J. Metcalf
ZWZena Werb
Zena Werb
Tissues are dynamically shaped by bidirectional communication between resident cells and the extracellular matrix (ECM) through cell-matrix interactions and ECM remodelling. Tumours leverage ECM remodelling to create a microenvironment that promotes tumourigenesis and metastasis. In this review, we focus on how tumour and tumour-associated stromal cells deposit, biochemically and biophysically modify, and degrade tumour-associated ECM. These tumour-driven changes support tumour growth, increase migration of tumour cells, and remodel the ECM in distant organs to allow for metastatic progression. A better understanding of the underlying mechanisms of tumourigenic ECM remodelling is crucial for developing therapeutic treatments for patients.

17 June 2019 in Nature Methods
Verified
Journal Article
Closed access
PDF file
CMChristopher S. McGinnis
Christopher S. McGinnis
DPDavid M. Patterson
David M. Patterson
JWJuliane Winkler
Juliane Winkler
DCDaniel N. Conrad
Daniel N. Conrad
MHMarco Y. Hein
Marco Y. Hein
ZGZev J. Gartner
Zev J. Gartner

27 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJoyce V. Lee
Joyce V. Lee
FHFilomena Housley
Filomena Housley
CYChristina Yau
Christina Yau
RNRachel Nakagawa
Rachel Nakagawa
JWJuliane Winkler
Juliane Winkler
AGAndrei Goga
Andrei Goga
Few patients with triple negative breast cancer (TNBC) benefit from immune checkpoint inhibitors with complete and durable remissions being quite rare. Oncogenes can regulate tumor immune infiltration, however whether oncogenes dictate diminished response to immunotherapy and whether these effects are reversible remains poorly understood. Here, we report that TNBCs with elevated MYC expression are resistant to immune checkpoint inhibitor therapy. Using mouse models and patient data, we show that MYC signaling is associated with low tumor cell PD-L1, low overall immune cell infiltration, and low tumor cell MHC-I expression. Restoring interferon signaling in the tumor increases MHC-I expression. By combining a TLR9 agonist and an agonistic antibody against OX40 with anti-PD-L1, mice experience tumor regression and are protected from new TNBC tumor outgrowth. Our findings demonstrate that MYC-dependent immune evasion is reversible and druggable, and when strategically targeted, may improve outcomes for patients treated with immune checkpoint inhibitors.

30 May 2024 in Cancer Cell
Verified
Journal Article
Closed access
CMChristopher S. McGinnis
Christopher S. McGinnis
ZMZhuang Miao
Zhuang Miao
DSDaphne Superville
Daphne Superville
WYWinnie Yao
Winnie Yao
AGAndrei Goga
Andrei Goga
ASAnsuman T. Satpathy
Ansuman T. Satpathy

9 March 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JWJuliane Winkler
Juliane Winkler
PLPengyuan Liu
Pengyuan Liu
KPKiet Phong
Kiet Phong
JHJohanna H. Hinrichs
Johanna H. Hinrichs
NANassim Ataii
Nassim Ataii
ZWZena Werb
Zena Werb
Significance: Bisphenol A (BPA), found in many plastic products, has weak estrogenic effects that can be harmful to human health. Thus, structurally related replacements—bisphenol S (BPS) and bisphenol F (BPF)—are coming into wider use with very few data about their biological activities. Here, we compared the effects of BPA, BPS, and BPF on human mammary organoids established from normal breast tissue. BPS disrupted organoid architecture and induced supernumerary branching. At a proteomic level, the bisphenols altered the abundance of common targets and those that were unique to each compound. The latter included proteins linked to tumor-promoting processes. These data highlighted the importance of testing the human health effects of replacements that are structurally related to chemicals of concern.

8 May 2023 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
ANAlbertas Navickas
Albertas Navickas
HAHosseinali Asgharian
Hosseinali Asgharian
JWJuliane Winkler
Juliane Winkler
LFLisa Fish
Lisa Fish
KGKristle Garcia
Kristle Garcia
HGHani Goodarzi
Hani Goodarzi
Cancer cells often co-opt post-transcriptional regulatory mechanisms to achieve pathologic expression of gene networks that drive metastasis. Translational control is a major regulatory hub in oncogenesis; however, its effects on cancer progression remain poorly understood. Here, to address this, we used ribosome profiling to compare genome-wide translation efficiencies of poorly and highly metastatic breast cancer cells and patient-derived xenografts. We developed dedicated regression-based methods to analyse ribosome profiling and alternative polyadenylation data, and identified heterogeneous nuclear ribonucleoprotein C (HNRNPC) as a translational controller of a specific mRNA regulon. We found that HNRNPC is downregulated in highly metastatic cells, which causes HNRNPC-bound mRNAs to undergo 3′ untranslated region lengthening and, subsequently, translational repression. We showed that modulating HNRNPC expression impacts the metastatic capacity of breast cancer cells in xenograft mouse models. In addition, the reduced expression of HNRNPC and its regulon is associated with the worse prognosis in breast cancer patient cohorts.